{"url":"https://lda.senate.gov/api/v1/filings/bca58912-e5d9-48fe-8531-e3e49af092df/","filing_uuid":"bca58912-e5d9-48fe-8531-e3e49af092df","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2023,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/bca58912-e5d9-48fe-8531-e3e49af092df/print/","filing_document_content_type":"text/html","income":null,"expenses":"40000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"John Bardi","dt_posted":"2023-07-17T17:44:49-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"430 East 29th Street","registrant_address_2":"Suite 900","registrant_different_address":false,"registrant_city":"New York","registrant_state":"NY","registrant_zip":"10016","registrant":{"id":401106431,"url":"https://lda.senate.gov/api/v1/registrants/401106431/","house_registrant_id":45487,"name":"INTRA-CELLULAR THERAPIES, INC.","description":null,"address_1":"430 East 29th Street","address_2":"Suite 900","address_3":null,"address_4":null,"city":"New York","state":"NY","state_display":"New York","zip":"10016","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JOHN BARDI","contact_telephone":"+1 646-477-0108","dt_updated":"2026-04-08T09:14:48.736683-04:00"},"client":{"id":44412,"url":"https://lda.senate.gov/api/v1/clients/44412/","client_id":44412,"name":"INTRA-CELLULAR THERAPIES, INC.","general_description":"Biopharmaceutical company","client_government_entity":null,"client_self_select":true,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2022-02-17"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"P.L. 117-169: Legislation not yet introduced; Negotiation regarding IRA Maximum Fair Price (MFP) and small manufacturer exception; Part D6 protected classes resolution.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":122308,"prefix":null,"prefix_display":null,"first_name":"ANDREW","nickname":null,"middle_name":null,"last_name":"SPERLING","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"HR 2630/S. 652: Safe Step Act - provisions regarding protocol for step therapy in pharmacy benefits. S. 1339: Pharmacy Benefit Manager Reform Act - provisions regarding regulation of pharmacy benefit managers.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":122308,"prefix":null,"prefix_display":null,"first_name":"ANDREW","nickname":null,"middle_name":null,"last_name":"SPERLING","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"HR 3938/S. 866: American Innovation and Jobs Act - provisions regarding research and development tax credit amortization.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":122308,"prefix":null,"prefix_display":null,"first_name":"ANDREW","nickname":null,"middle_name":null,"last_name":"SPERLING","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}